Hoyme U B, Hagedorn M, Schindler A E, Schneede P, Hopfenmüller W, Schorn K, Eul A
Department of Obstetrics and Gynecology, Helios Klinikum Erfurt, Germany.
Infect Dis Obstet Gynecol. 2002;10(2):79-88. doi: 10.1155/S1064744902000066.
Imiquimod is an immune response modifier that has demonstrated a good efficacy and relatively low recurrence rates in comparison to other genital wart treatment modalities. The primary objective of this open-label study was to evaluate the effect on sustained clearance of treated lesions and the safety of patient-applied topical imiquimod after laser therapy of external anogenital warts.
After laser treatment of visible external anogenital warts the ablated region(s) were treated with imiquimod 5% cream three times/week over 12 weeks beginning when the wound healing process was completed, followed by a six-month treatment-free observation period for the assessment of sustained clearance of treated lesions.
A total of 211 male and female patients was enrolled in the study. After 12 weeks of treatment, 65.4% of all patients showed sustained clearance. During the treatment period, 15 patients (7.1% of 211 patients) presented with recurrent warts in the treated areas, and 58 (27.5%) patients were excluded for other reasons. During the six-month follow-up period, ten additional patients (7.3% of 138 patients) developed wart recurrences. The application of imiquimod 5% cream was well tolerated. The number of patients with adverse events related to study medication declined from the first month of treatment until the end of the third month. Most frequently, mild to moderate itching, burning, pain and erythema were reported.
After laser therapy and sufficient wound healing, administration of imiquimod 5% cream three times/week appears to be safe and to reduce the incidence of wart recurrences.
咪喹莫特是一种免疫反应调节剂，与其他尖锐湿疣治疗方式相比，已显示出良好的疗效和相对较低的复发率。这项开放标签研究的主要目的是评估外用咪喹莫特乳膏患者自行给药在激光治疗外生殖器疣后对治疗病灶持续清除的效果及安全性。
在对可见的外生殖器疣进行激光治疗后，从伤口愈合过程完成时开始，在12周内每周3次用5%咪喹莫特乳膏治疗烧灼区域，随后有一个为期6个月的无治疗观察期，以评估治疗病灶的持续清除情况。
共有211名男性和女性患者纳入该研究。治疗12周后，所有患者中有65.4%显示病灶持续清除。在治疗期间，15名患者（211名患者中的7.1%）在治疗区域出现疣体复发，58名（27.5%）患者因其他原因被排除。在6个月的随访期内，又有10名患者（138名患者中的7.3%）出现疣体复发。5%咪喹莫特乳膏的应用耐受性良好。与研究药物相关的不良事件患者数量从治疗的第一个月到第三个月末有所下降。最常报告的是轻度至中度瘙痒、灼痛、疼痛和红斑。
激光治疗且伤口充分愈合后，每周3次给予5%咪喹莫特乳膏似乎是安全的，并可降低疣体复发率。
